The content of this website has been produced in line with the BESPONSA®▼ (inotuzumab ozogamicin) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BESPONSA▼ Prescribing Information for Great Britain click here. BESPONSA▼ Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.
Access the Guidelines
NICE Recommended1:
BESPONSA (inotuzumab oxogamicin) is recommended as an option for treating relapsed or refractory CD22-positive B-call precursor acute lymphoblastic leukaemia in adults. People with relapsed or refractory Philadelphia chromosome positive disease should have had at least 1 tyrosine kinase inhibitor.
Scottish Medicine Consortium (SMC)2
Advice: following a full submission assessed under the ultra-orphan and end of life medicine process:
Inotuzumab ozogamicin (BESPONSA) is accepted for restricted use within NHS Scotland.
Indication under review: as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive relapsed or refractory B cell precursor ALL should have failed treatment with at least one tyrosine kinase inhibitor.
SMC restriction: in patients for whom the intent is to proceed to stem cell transplantation.
A phase III open label randomised controlled study demonstrated improvements in remission rates and overall survival for the patient population under review when treated with inotuzumab ozogamicin compared with standard chemotherapy.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of inotuzumab ozogamicin. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting
Developments in Leukaemia Care
Watch Professor David Marks discuss targeted therapies and the INO-VATE study, including 3 year follow up and impact of allogeneic bone marrow transplantation on survival
Management of Refractory/Relapsed ALL
Hear Professor David Marks discuss the INO-VATE study including MRD negativity, long term survival and reducing risks of veno-occlusive disease
- NICE Technology Appraisal Guidance (TA541). Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia. Available at: https://www.nice.org.uk/guidance/TA541 Published: 19 September 2018. [accessed August 2021].
- Scottish Medicines Consortium. Inotuzumab ozogamicin (BESPONSA): 1328/18 (Published: 11 June 2018). Available at: https://www.scottishmedicines.org.uk/medicines-advice/inotuzumab-ozogamicin-besponsa-fullsubmission-132818/ [accessed August 2021].
Quick Links
Fast Facts
Download the Fast Facts Guide holding the key information for BESPONSA including mode of action, INO-VATE study design, INO-VATE results; efficacy and safety profile. Summary of Product Characteristics (SmPC) should be consulted for full guidance.
For UK Healthcare Professionals*
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021
No